Acute symptoms in SARS-CoV-2 positive adolescents aged 15–18 years – Results from a Danish national cross-sectional survey study

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Acute symptoms in SARS-CoV-2 positive adolescents aged 15–18 years – Results from a Danish national cross-sectional survey study. / Berg, Selina Kikkenborg; Palm, Pernille; Nielsen, Susanne Dam; Nygaard, Ulrikka; Bundgaard, Henning; Rotvig, Camilla; Christensen, Anne Vinggaard.

In: The Lancet Regional Health - Europe, Vol. 16, 100354, 2022.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Berg, SK, Palm, P, Nielsen, SD, Nygaard, U, Bundgaard, H, Rotvig, C & Christensen, AV 2022, 'Acute symptoms in SARS-CoV-2 positive adolescents aged 15–18 years – Results from a Danish national cross-sectional survey study', The Lancet Regional Health - Europe, vol. 16, 100354. https://doi.org/10.1016/j.lanepe.2022.100354

APA

Berg, S. K., Palm, P., Nielsen, S. D., Nygaard, U., Bundgaard, H., Rotvig, C., & Christensen, A. V. (2022). Acute symptoms in SARS-CoV-2 positive adolescents aged 15–18 years – Results from a Danish national cross-sectional survey study. The Lancet Regional Health - Europe, 16, [100354]. https://doi.org/10.1016/j.lanepe.2022.100354

Vancouver

Berg SK, Palm P, Nielsen SD, Nygaard U, Bundgaard H, Rotvig C et al. Acute symptoms in SARS-CoV-2 positive adolescents aged 15–18 years – Results from a Danish national cross-sectional survey study. The Lancet Regional Health - Europe. 2022;16. 100354. https://doi.org/10.1016/j.lanepe.2022.100354

Author

Berg, Selina Kikkenborg ; Palm, Pernille ; Nielsen, Susanne Dam ; Nygaard, Ulrikka ; Bundgaard, Henning ; Rotvig, Camilla ; Christensen, Anne Vinggaard. / Acute symptoms in SARS-CoV-2 positive adolescents aged 15–18 years – Results from a Danish national cross-sectional survey study. In: The Lancet Regional Health - Europe. 2022 ; Vol. 16.

Bibtex

@article{0837467f76a64d1581d9237ce3a0c984,
title = "Acute symptoms in SARS-CoV-2 positive adolescents aged 15–18 years – Results from a Danish national cross-sectional survey study",
abstract = "Background: The purpose of this study was to investigate prevalence of self-reported symptom burden during the acute phase of SARS-CoV-2 infection and associated factors including sex differences. Methods: All Danish adolescents aged 15–18 years with laboratory confirmed SARS-CoV-2 infection between January 2020 and July 2021 were invited to participate. A survey covered the initial four weeks of SARS-CoV-2 infection and included questions regarding 17 symptoms associated with acute COVID-19, symptom burden and medical history. Statistical analyses included descriptive statistics and logistic regression. Findings: A total of 24,315 adolescents with SARS-CoV-2 infection were invited and 6630 (27.3%) completed the questionnaire. The median age was 17.6 years, and 58.4% (n = 3873) were female. No symptoms were reported by 33.8% (n = 2241), mild perceived symptom burden by 57.2%(n = 3775), and severe symptom burden by 9.0 % (n = 594). Two thirds (n = 2999) of the symptomatic participants reported a symptom duration of 1–10 days. The most prevalent symptoms included headaches 39.2% (n = 2597), a reduced sense of smell 36.2% (n = 2398), cough 31.6% (n = 2093), sore throat 31.1% (n = 2063), and a reduced sense of taste 31.1% (n = 2062). Adolescents at the age of 18 years had higher odds of reporting ≥6 symptoms OR1.47 (95%CI, 1.23–1.76), p < 0.0001 and adolescents 18+ years old had higher odds of reporting a severe symptom burden OR1.98 (95%CI, 1.43–2.73) compared to the 15years old adolescents. A history of OCD/anxiety/depression was associated with reporting ≥6 symptoms OR 1.67 (95%CI, 1.34–2.09), p < 0.0001 and a history of allergy and OCD/anxiety/depression reporting severe symptom burden OR 1.64 (95%CI, 1.35–1.99), p < 0.0001 and OR 1.75 (95%CI, 1.28–2.36), p = 0.0004. Females reported more symptoms than males; median of three (IQR 0–6) vs. a median of two (IQR 0–4) symptoms, p < 0.0001. Interpretation: Two in three experienced symptoms and the majority reported mild symptom burden. Headache, a reduced sense of smell and taste, cough and sore throat were most common. Female sex, asthma and previous Epstein-Barr virus were associated with more symptoms and higher symptom burden. Funding: The study was funded by the AP M{\o}ller Foundation. The research was investigator initiated. The study funder played no role in the study.",
author = "Berg, {Selina Kikkenborg} and Pernille Palm and Nielsen, {Susanne Dam} and Ulrikka Nygaard and Henning Bundgaard and Camilla Rotvig and Christensen, {Anne Vinggaard}",
note = "Publisher Copyright: {\textcopyright} 2022 The Authors",
year = "2022",
doi = "10.1016/j.lanepe.2022.100354",
language = "English",
volume = "16",
journal = "The Lancet Regional Health - Europe",
issn = "2666-7762",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Acute symptoms in SARS-CoV-2 positive adolescents aged 15–18 years – Results from a Danish national cross-sectional survey study

AU - Berg, Selina Kikkenborg

AU - Palm, Pernille

AU - Nielsen, Susanne Dam

AU - Nygaard, Ulrikka

AU - Bundgaard, Henning

AU - Rotvig, Camilla

AU - Christensen, Anne Vinggaard

N1 - Publisher Copyright: © 2022 The Authors

PY - 2022

Y1 - 2022

N2 - Background: The purpose of this study was to investigate prevalence of self-reported symptom burden during the acute phase of SARS-CoV-2 infection and associated factors including sex differences. Methods: All Danish adolescents aged 15–18 years with laboratory confirmed SARS-CoV-2 infection between January 2020 and July 2021 were invited to participate. A survey covered the initial four weeks of SARS-CoV-2 infection and included questions regarding 17 symptoms associated with acute COVID-19, symptom burden and medical history. Statistical analyses included descriptive statistics and logistic regression. Findings: A total of 24,315 adolescents with SARS-CoV-2 infection were invited and 6630 (27.3%) completed the questionnaire. The median age was 17.6 years, and 58.4% (n = 3873) were female. No symptoms were reported by 33.8% (n = 2241), mild perceived symptom burden by 57.2%(n = 3775), and severe symptom burden by 9.0 % (n = 594). Two thirds (n = 2999) of the symptomatic participants reported a symptom duration of 1–10 days. The most prevalent symptoms included headaches 39.2% (n = 2597), a reduced sense of smell 36.2% (n = 2398), cough 31.6% (n = 2093), sore throat 31.1% (n = 2063), and a reduced sense of taste 31.1% (n = 2062). Adolescents at the age of 18 years had higher odds of reporting ≥6 symptoms OR1.47 (95%CI, 1.23–1.76), p < 0.0001 and adolescents 18+ years old had higher odds of reporting a severe symptom burden OR1.98 (95%CI, 1.43–2.73) compared to the 15years old adolescents. A history of OCD/anxiety/depression was associated with reporting ≥6 symptoms OR 1.67 (95%CI, 1.34–2.09), p < 0.0001 and a history of allergy and OCD/anxiety/depression reporting severe symptom burden OR 1.64 (95%CI, 1.35–1.99), p < 0.0001 and OR 1.75 (95%CI, 1.28–2.36), p = 0.0004. Females reported more symptoms than males; median of three (IQR 0–6) vs. a median of two (IQR 0–4) symptoms, p < 0.0001. Interpretation: Two in three experienced symptoms and the majority reported mild symptom burden. Headache, a reduced sense of smell and taste, cough and sore throat were most common. Female sex, asthma and previous Epstein-Barr virus were associated with more symptoms and higher symptom burden. Funding: The study was funded by the AP Møller Foundation. The research was investigator initiated. The study funder played no role in the study.

AB - Background: The purpose of this study was to investigate prevalence of self-reported symptom burden during the acute phase of SARS-CoV-2 infection and associated factors including sex differences. Methods: All Danish adolescents aged 15–18 years with laboratory confirmed SARS-CoV-2 infection between January 2020 and July 2021 were invited to participate. A survey covered the initial four weeks of SARS-CoV-2 infection and included questions regarding 17 symptoms associated with acute COVID-19, symptom burden and medical history. Statistical analyses included descriptive statistics and logistic regression. Findings: A total of 24,315 adolescents with SARS-CoV-2 infection were invited and 6630 (27.3%) completed the questionnaire. The median age was 17.6 years, and 58.4% (n = 3873) were female. No symptoms were reported by 33.8% (n = 2241), mild perceived symptom burden by 57.2%(n = 3775), and severe symptom burden by 9.0 % (n = 594). Two thirds (n = 2999) of the symptomatic participants reported a symptom duration of 1–10 days. The most prevalent symptoms included headaches 39.2% (n = 2597), a reduced sense of smell 36.2% (n = 2398), cough 31.6% (n = 2093), sore throat 31.1% (n = 2063), and a reduced sense of taste 31.1% (n = 2062). Adolescents at the age of 18 years had higher odds of reporting ≥6 symptoms OR1.47 (95%CI, 1.23–1.76), p < 0.0001 and adolescents 18+ years old had higher odds of reporting a severe symptom burden OR1.98 (95%CI, 1.43–2.73) compared to the 15years old adolescents. A history of OCD/anxiety/depression was associated with reporting ≥6 symptoms OR 1.67 (95%CI, 1.34–2.09), p < 0.0001 and a history of allergy and OCD/anxiety/depression reporting severe symptom burden OR 1.64 (95%CI, 1.35–1.99), p < 0.0001 and OR 1.75 (95%CI, 1.28–2.36), p = 0.0004. Females reported more symptoms than males; median of three (IQR 0–6) vs. a median of two (IQR 0–4) symptoms, p < 0.0001. Interpretation: Two in three experienced symptoms and the majority reported mild symptom burden. Headache, a reduced sense of smell and taste, cough and sore throat were most common. Female sex, asthma and previous Epstein-Barr virus were associated with more symptoms and higher symptom burden. Funding: The study was funded by the AP Møller Foundation. The research was investigator initiated. The study funder played no role in the study.

U2 - 10.1016/j.lanepe.2022.100354

DO - 10.1016/j.lanepe.2022.100354

M3 - Journal article

C2 - 35350632

AN - SCOPUS:85126958464

VL - 16

JO - The Lancet Regional Health - Europe

JF - The Lancet Regional Health - Europe

SN - 2666-7762

M1 - 100354

ER -

ID: 314841938